1 min read

ID: 1113483

Short Link: https://gregory-ms.com/articles/1113483/

Discovery Date: 28 November 2022, 06:00:17 UTC

Published Date: 2022-11-27 11:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/36437270/?fc=20210216052009&ff=20221128010009&v=2.17.8

Manual Selection: none

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Sci Rep. 2022 Nov 27;12(1):20411. doi: 10.1038/s41598-022-24617-4.

ABSTRACT

Here we present a comprehensive mass cytometry analysis of peripheral innate lymphoid cell (ILC) subsets in relapsing/remitting MS (RRMS) patients prior to and after onset of cladribine tablets (CladT). ILC analysis was conducted on CyTOF data from peripheral blood mononuclear cells (PBMC) of MS patients before, 2 and 6 months after onset of CladT, and non-MS controls. Dimensionality reduction was used for immunophenotyping ILC subsets. CladT reduced all ILC subsets, except for CD56bright NK cells and ILC2. Furthermore, CD38+ NK cell and CCR6+ ILC3 were excluded from CladT-induced immune cell reductions. Post-CladT replenishment by immature ILC was noted by increased CD5+ ILC1 proportions at 2 months, and boosted CD38-CD56bright NK cell numbers at 6 months. CladT induce immune cell depletion among ILC but exclude CD56bright NK cells and ILC2 subsets, as well as CD38+ NK cell and CCR6+ ILC3 immunophenotypes. Post-CladT ILC expansions indicate ILC reconstitution towards a more tolerant immune system phenotype.

PMID:36437270 | DOI:10.1038/s41598-022-24617-4

Noun Phrases in Title

  • Mass cytometry
  • cladribine-induced resets
  • innate lymphoid cells
  • multiple sclerosis
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.